GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Charles River Laboratories International Inc (NYSE:CRL) » Definitions » Peter Lynch Fair Value

Charles River Laboratories International (Charles River Laboratories International) Peter Lynch Fair Value

: $185.37 (As of Today)
View and export this data going back to 2000. Start your Free Trial

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Charles River Laboratories International's PEG is 1. Charles River Laboratories International's 5-Year TTM EBITDA Growth Rate is 16.76. Charles River Laboratories International's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $11.06. Therefore, the Peter Lynch Fair Value for today is $185.37.

As of today (2024-04-16), Charles River Laboratories International's share price is $235.93. Charles River Laboratories International's Peter Lynch fair value is $185.37. Therefore, Charles River Laboratories International's Price to Peter Lynch Fair Value Ratio for today is 1.27.


The historical rank and industry rank for Charles River Laboratories International's Peter Lynch Fair Value or its related term are showing as below:

CRL' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.27   Med: 1.78   Max: 3.28
Current: 1.27


During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Charles River Laboratories International was 3.28. The lowest was 1.27. And the median was 1.78.


CRL's Price-to-Peter-Lynch-Fair-Value is ranked better than
60.78% of 51 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.64 vs CRL: 1.27

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Charles River Laboratories International Peter Lynch Fair Value Historical Data

The historical data trend for Charles River Laboratories International's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Charles River Laboratories International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.24 100.01 115.01 145.64 185.37

Charles River Laboratories International Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Peter Lynch Fair Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 145.64 154.80 165.58 179.40 185.37

Competitive Comparison

For the Diagnostics & Research subindustry, Charles River Laboratories International's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Charles River Laboratories International Price-to-Peter-Lynch-Fair-Value Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Charles River Laboratories International's Price-to-Peter-Lynch-Fair-Value falls into.



Charles River Laboratories International Peter Lynch Fair Value Calculation

Charles River Laboratories International's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 16.76 *11.06
=185.37

Charles River Laboratories International's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.06.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Charles River Laboratories International  (NYSE:CRL) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 16.76 instead of 15 in this case.

Charles River Laboratories International's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=235.93/185.37
=1.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Charles River Laboratories International Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Charles River Laboratories International's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Charles River Laboratories International (Charles River Laboratories International) Business Description

Traded in Other Exchanges
Address
251 Ballardvale Street, Wilmington, MA, USA, 01887
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Executives
Victoria L Creamer officer: EVP & Chief People Officer 164 PINE HILL ROAD, NEW FAIRFIELD CT 06812
Joseph W Laplume officer: EVP, Corp Strategy & Develop 251 BALLARDVALE STREET, WILMINGTON MA 01887
Birgit Girshick officer: Corporate Executive VP 251 BALLARDVALE STREET, WILMINGTON MA 01887
James C Foster director, officer: President and CEO 251 BALLARDVALE ST, WILMINGTON MA 01887
Richard F Wallman director HONEYWELL, 101 COLUMBIA ROAD, MORRISTOWN NJ 07962
William D Barbo officer: Corporate Executive VP & CCO 251 BALLARDVALE STREET, WILMINGTON MA 01887
Michael Gunnar Knell officer: CSVP&Chief Accounting Officer BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
George Massaro director
Shannon M Parisotto officer: CEVP, Disc & Safety Assessment 251 BALLARDVALE ST, WILMINGTON MA 01887
Flavia Pease officer: Corporate Executive VP 251 BALLARDVALE STREET, WILMINGTON MA 01887
David Ross Smith officer: Corporate Executive VP & CFO 251 BALLARDVALE STREET, WILMINGTON MA 01887
Deborah Turner Kochevar director 251 BALLARDVALE STREET, WILMINGTON MA 01887
Milne George M Jr director
Stephen D Chubb director C/O MATRITECH INC, 330 NEVADA STREET, NEWTON MA 02460
George Llado director 251 BALLARDVALE STREET, WILMINGTON MA 01887